Shots:
- The US FDA has approved Xolremdi (mavorixafor) capsules for treating WHIM syndrome patients (12yrs. & above) and granted a Rare Pediatric Disease Priority Review Voucher to the company
- The approval was supported by the P-III (4WHIM) study assessing the safety & efficacy of Xolremdi vs PBO to treat WHIM syndrome patients (n=31, 12yrs. & above)
- The study depicted an increase in time above threshold for absolute neutrophil count (TAT-ANC) & absolute lymphocyte count (TAT-ALC), total infection score reduction by ~40% and an annualized infection rate reduction by 60% with no difference in total wart change scores over 52wks.
Ref: X4 Pharmaceuticals | Image: X4 Pharmaceuticals| Press Release
Related News:- Bausch + Lomb’s Lumify Receives the US FDA’s Approval to Treat Ocular Redness
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
